Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes ...

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...

Phio Pharmaceuticals stock drops 39.1% after announcing a $3.19 million direct offering and concurrent private placement.

Greenwich LifeSciences (GLSI), focused on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast ...

A new study published in the journal of Cancer Medicine found that in patients with breast cancer undergoing neoadjuvant ...

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Researchers found that receipt of neoadjuvant and adjuvant chemotherapy were associated with inadequate ovarian function suppression. Researchers say they have identified several factors that may be ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

The investigators evaluated the feasibility and capacity of the RAD51 test to predict which patients with early-stage breast ...

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the ...